Chimeric antigen receptor targeting oncolytic virus-derived protein, immunocyte expressing same, and uses of both

Abstract

A chimeric antigen receptor targeting an oncolytic virus-derived protein, an immune cell expressing the same, and uses thereof are disclosed. The chimeric antigen receptor-expressing immune cell can effectively target the protein A56 that is specifically expressed on the cancer cell surface, which enables targeted therapy for cancer cells that have survived even infection with an oncolytic virus, thereby providing effective anticancer therapy. The chimeric antigen receptor-expressing immune cell can have increased activation and proliferation capacity specifically for protein A56 and exhibit excellent cytotoxic effects, thereby providing effective anticancer therapy against protein A56-expressing cancer cells. The immune cell is preferably used in combination with an oncolytic virus, and may be additionally used in combination with a drug capable of enhancing an anticancer effect of the oncolytic virus (for example, hydroxyurea, chemotherapeutic agents for regulating lymphocyte removal (for example, cyclophosphamide and fludarabine), or immunotherapeutic agents).

Dependencies are inferred from the claim text.